Interestingly, FAS inhibition was previously demonstrated to improve non-alcoholic fatty liver diseases and non-alcoholic steatohepatitis by reducing inflammatory markers IL-1β and reducing transaminitis (elevated serum ALT and AST)60,65. Here, IL1B is linked to metabolic dysfunction-associated steatohepatitis.